Apaxen is a preclinical stage biotechnology company developing unique anti-inflammatory therapeutics with a primary focus on pulmonary arterial hypertension (PAH). It developed a first-in-class small molecule inhibitors of pleiotropic pro-inflammatory cytokine “Macrophage migration Inhibitory Factor (MIF)”, a crucial regulator of innate immune responses. Apaxen’s lead compound MFC-1040 has a unique mechanism of action and has the potential to revolutionise the standard of care of PAH and other diseases related to chronic inflammation.

For more information: Apaxen